Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) SVP Jonathan Rubin Sells 927 Shares

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) SVP Jonathan Rubin sold 927 shares of the stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $39.15, for a total transaction of $36,292.05. Following the completion of the sale, the senior vice president now owns 7,853 shares in the company, valued at $307,444.95. This represents a 10.56 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Supernus Pharmaceuticals Stock Performance

Supernus Pharmaceuticals stock opened at $32.68 on Tuesday. The firm’s fifty day moving average price is $37.41 and its 200-day moving average price is $35.39. The stock has a market cap of $1.80 billion, a P/E ratio of 30.54 and a beta of 0.90. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $25.53 and a fifty-two week high of $40.28.

Institutional Trading of Supernus Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Vident Advisory LLC raised its position in shares of Supernus Pharmaceuticals by 2.2% during the 4th quarter. Vident Advisory LLC now owns 14,392 shares of the specialty pharmaceutical company’s stock valued at $520,000 after buying an additional 309 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Supernus Pharmaceuticals by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,993 shares of the specialty pharmaceutical company’s stock valued at $61,000 after buying an additional 352 shares in the last quarter. Summit Investment Advisors Inc. raised its position in shares of Supernus Pharmaceuticals by 7.6% during the 4th quarter. Summit Investment Advisors Inc. now owns 5,253 shares of the specialty pharmaceutical company’s stock valued at $190,000 after buying an additional 369 shares in the last quarter. Bank of Montreal Can raised its position in shares of Supernus Pharmaceuticals by 6.6% during the 4th quarter. Bank of Montreal Can now owns 7,595 shares of the specialty pharmaceutical company’s stock valued at $275,000 after buying an additional 473 shares in the last quarter. Finally, Exchange Traded Concepts LLC grew its holdings in shares of Supernus Pharmaceuticals by 2.6% during the 4th quarter. Exchange Traded Concepts LLC now owns 22,119 shares of the specialty pharmaceutical company’s stock valued at $800,000 after purchasing an additional 560 shares during the last quarter.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald cut shares of Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and lowered their target price for the stock from $57.00 to $36.00 in a research note on Wednesday, February 19th.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.